Vanda Pharmaceuticals (VNDA) Gross Margin (2010 - 2026)
Vanda Pharmaceuticals (VNDA) posted Gross Margin of 93.89% for Q1 2026, up 0.63% sequentially from 93.3% in Q4 2025, and up 93.0% YoY from 48.65% in Q1 2025.
Vanda Pharmaceuticals (VNDA) Gross Margin (2010 - 2026) Analysis & Trends
Vanda Pharmaceuticals has reported Gross Margin for 14 years, with the latest figure at 93.89% in Q1 2026.
- Quarterly Gross Margin rose 93.0% year-over-year to 93.89% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 94.18% (down 16.0% YoY) and the FY2025 annual result came in at 93.96%, down 34.0% from the prior year.
- Gross Margin rose to 93.89% in Q1 2026 per VNDA's latest filing, from 93.3% in the prior quarter.
- Over five years, Gross Margin peaked at 95.13% in Q4 2024 and troughed at 90.32% in Q3 2022.
- A 5-year average of 92.82% and a median of 92.75% in 2024 frame the typical range for Gross Margin.
- The sharpest annual moves came in 2024 and 2025: Gross Margin jumped 277 bps in 2024, then plunged 183 bps in 2025.
- Over 5 years, Gross Margin stood at 90.33% in 2022, then gained by 2 bps to 92.36% in 2023, then climbed by 3 bps to 95.13% in 2024, then slipped by 2 bps to 93.3% in 2025, then increased by 1 bps to 93.89% in 2026.
- According to Business Quant data, Gross Margin over the past three periods registered 93.89%, 93.3%, and 94.75% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 90.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 89.76% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 60,631,834.75% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 76.90% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 84.20% |
| 10 | Vanda Pharmaceuticals | 315.57 Mn | 145.54 Mn | 46.97 Mn | 92.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 92.95% |
| Mar 31, 2026 | 93.89% |
| Dec 31, 2025 | 93.30% |
| Sep 30, 2025 | 94.75% |
| Jun 30, 2025 | 94.80% |
| Mar 31, 2025 | 92.96% |
| Dec 31, 2024 | 95.13% |
| Sep 30, 2024 | 94.65% |
| Jun 30, 2024 | 94.59% |
| Mar 31, 2024 | 92.75% |
| Dec 31, 2023 | 92.36% |
| Sep 30, 2023 | 92.11% |
| Jun 30, 2023 | 92.40% |
| Mar 31, 2023 | 92.36% |
| Dec 31, 2022 | 90.33% |
| Sep 30, 2022 | 90.32% |
| Jun 30, 2022 | 90.59% |
| Mar 31, 2022 | 90.59% |
| Dec 31, 2021 | 90.83% |
| Sep 30, 2021 | 90.30% |